This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verheijen, R. H. Search for Related Content PubMed Articles by Verheijen, R. H. Related Articles Related Correspondence Social Bookmarking                            What's this?

In Reply

VU University Medical Center, Amsterdam, the Netherlands

Leon F. Massuger

Radboud University Medical Center, Nijmegen, the Netherlands

Benedict B. Benigno

Southeastern Gynecologic Oncology, Atlanta, GA

Alberto Lopes

Northern Gynaecological Oncology Center, Queen Elizabeth Hospital, Tyne & Wear, United Kingdom

Michael V. Seiden

Massachusetts General Hospital, Boston, MA

The SMART Study Group

We appreciate and acknowledge that the Nicholson et al abstract presented at the 36th Annual Meeting of the American Society of Clinical Oncology in New Orleans, LA, May 20-23, 2000¹ indeed accurately predicted the outcome of our large, well-powered study.² We could and would, however, not refer to their predictive results as these had not been fully published in a peer-reviewed journal, due to the lack of completeness which Nicholson claims. Unfortunately, both their study and our study have been unable to show a survival benefit for females with ovarian cancer treated with intraperitoneal radioimmunotherapy. However, with transparent and complete disclosure of all the information, we still hope to benefit patients in the longer term.

Authors' Disclosures of Potential Conflicts of Interest

Authors Employment Leadership Consultant Stock Honoraria Research Funds Testimony Other René H. Verheijen Antisoma (B) Leon F. Massuger Antisoma (B) Benedict B. Benigno Antisoma (B) Alberto Lopes Antisoma (B) Michael V. Seiden Antisoma (A)

Dollar Amount Codes (A) < $10,000 (B) $10,000-99,999 (C) $100,000 (N/R) Not Required

ACKNOWLEDGMENTS

This study was supported by Antisoma Ltd, London, United Kingdom, and Hoffmann-La Roche Inc, Basel, Switzerland. The authors represented the SMART study group in this trial.

REFERENCES

1. Nicholson S, Bell SJ, McCormack M, et al: A randomised phase III trial of adjuvant intraperitoneal radioimmunotherapy in ovarian cancer. Proc Am Soc Clin Oncol 19:1514, 2000 (abstr 1514)

2. Verheijen RH, Massuger LF, Benigno BB, et al: Phase III trial of intraperitoneal therapy with Yttrium-90-labeled HMFGI1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24:571-578, 2006[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Not So "SMART"
  Steve Nicholson
  JCO 2006 24: 3511-3512 [Full Text]

This article has been cited by other articles:

				A. B. Benson III New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease Clin. Cancer Res., November 15, 2007; 13(22): 6913s - 6920s. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verheijen, R. H. Search for Related Content PubMed Articles by Verheijen, R. H. Related Articles Related Correspondence Social Bookmarking                            What's this?